Licorice Extract Isoliquiritigenin Protects Endothelial Function in Type 2 Diabetic Mice

Area of Science:

• Cardiovascular Biology
• Endocrinology
• Pharmacology

Background:

• Endothelial dysfunction precedes atherosclerosis and predicts cardiovascular diseases (CVDs).
• Diabetes mellitus exacerbates endothelial dysfunction via oxidative stress and inflammation.
• Isoliquiritigenin (ISL) is a licorice-derived compound with known anti-inflammatory and antioxidant properties.

Purpose of the Study:

• To investigate the therapeutic potential of ISL in ameliorating type 2 diabetes (T2D)-associated endothelial dysfunction.
• To elucidate the underlying mechanisms of ISL's action on vascular health in a T2D model.

Main Methods:

• Utilized a mouse model of T2D (db/db mice) and in vitro endothelial cell cultures (mBMECs).
• Induced endothelial dysfunction using Interleukin-1β (IL-1β).
• Assessed endothelium-dependent relaxations (EDRs), reactive oxygen species (ROS) levels, inflammatory markers (MCP-1, TNF-α, IL-6), NOX2 expression, and antioxidant-related factors (IL-10, SOD1, Nrf2, HO-1).

Main Results:

• ISL significantly improved EDRs in db/db mouse aortas.
• ISL treatment reduced ROS levels and attenuated pro-inflammatory cytokine overexpression in both animal and cellular models.
• ISL inhibited NOX2 expression and restored beneficial antioxidant and anti-inflammatory markers (IL-10, SOD1, Nrf2, HO-1).

Conclusions:

• ISL effectively attenuates endothelial dysfunction in a preclinical model of type 2 diabetes.
• ISL exerts its protective effects by mitigating oxidative stress, inflammation, and modulating key molecular pathways.
• ISL demonstrates significant potential as a therapeutic agent for T2D-related vascular complications.